Exhibit 99.1 Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update Upcoming Anticipated Milestones Q1 2025 Financial Results Research and Development (R&D) expenses decreased by $0.2 million to$2.3 million for the three months ended March 31, 2025, as compared to $2.5 million for the three months ended March 31, 2024. The decrease in research and development expenses was primarily related to recognition of research grant income, a tax rebate in Australia, and opti ...